| USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS |
USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS |
95%
|
USAspending awards from Department of Veterans Affairs: $10,380 across 2 awards. 36C24225N0241 SURGICAL IMPLANTS; 36C10G24N0024 BIOLOGICS AND NON-BIOLOGIC PROSTHETICS | Qwen corrected direction: Expl… |
| REGEN-LAB-USA-LLC |
REGEN-LAB-USA-LLC |
85%
|
ote matures in the second quarter of 2028, and contains certain contingent conversion features upon the occurrence of specified events. The Vaporox Note was funded early in the third quarter of 2025.… |
| IART |
Integra LifeSciences Holdings Corporation |
72%
|
ls increase their purchases of our products during the fourth quarter to coincide with the end of their budget cycles in the United States. Satisfaction of patient deductibles through the course of t… |
| IART |
Integra LifeSciences Holdings Corporation |
72%
|
Reciprocal relationship from IART graph: rganization, our innovative technologies, and our procurement and manufacturing operations to maintain our competitive position. Our competitors for TT includ… |
| SNNUF |
Smith & Nephew plc |
72%
|
Reciprocal relationship from SNNUF graph: Reciprocal relationship from MDXG graph: Reciprocal relationship from SNNUF graph: Reciprocal relationship from MDXG graph: ls increase their purchases of ou… |
| SNNUF |
Smith & Nephew plc |
72%
|
ls increase their purchases of our products during the fourth quarter to coincide with the end of their budget cycles in the United States. Satisfaction of patient deductibles through the course of t… |
| SNWV |
SANUWAVE Health, Inc. |
72%
|
Reciprocal relationship from SNWV graph: hree P’s.” • Patients want to get better sooner and to experience less pain. • Physicians want patients to get better but also need to be able to integrate ca… |
| TELA |
TELA Bio, Inc. |
72%
|
Reciprocal relationship from TELA graph: cost as a percentage of Aroa’s cost of goods sold, and subject to a true-up adjustment, resulting in an amount equal to 27% of our net sales of our OviTex and… |
| TELA |
TELA Bio, Inc. |
72%
|
was funded early in the third quarter of 2025. The Company elected to account for the Vaporox Note pursuant to the Fair Value Option guidance prescribed by Accounting Standards Codification (“ ASC ”)… |
| BOARD-EW-HEALTHCARE-PARTNERS |
BOARD-EW-HEALTHCARE-PARTNERS |
62%
|
Item 12, “ Security Ownership Of Certain Beneficial Owners And Management” below). Also, for as long as EW Healthcare Partners and its affiliates collectively hold at least (i) 10% of the outstanding… |
| EW-HEALTHCARE-PARTNERS |
EW-HEALTHCARE-PARTNERS |
62%
|
Item 12, “ Security Ownership Of Certain Beneficial Owners And Management” below). Also, for as long as EW Healthcare Partners and its affiliates collectively hold at least (i) 10% of the outstanding… |
| INTEGRA-LIFESCIENCES-HOLDINGS-CORPORATION-ORGANO |
INTEGRA-LIFESCIENCES-HOLDINGS-CORPORATION-ORGANO |
62%
|
cost-effective, and have the potential to improve patient outcomes and reduce the length of stay. We are working to develop additional health economic data to support this effort. As noted above, the… |
| REGENITY-BIOSCIENCES-INC |
REGENITY-BIOSCIENCES-INC |
62%
|
nufacturing and Supply Agreement (the “ TELA-Regenity Supply Agreement ”) between TELA and Regenity Biosciences, Inc. (“ Regenity ”), which retains all intellectual property rights and regulatory cle… |
| SURGENEX-LLC |
SURGENEX-LLC |
62%
|
ersonnel with access to our proprietary or confidential information are hired by our competitors, they may share such information with our competitors requiring us to initiate litigation to prevent a… |
